Last reviewed · How we verify
NCT07020962
Effect of Laughter Therapy on Breast Cancer Patients
NA trial testing laughter therapy in Laughter Therapy in 56 participants. Not yet recruiting.
30 August 2025
Quick facts
| Lead sponsor | Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 56 |
| Start date | 25 June 2025 |
| Primary completion | 30 August 2025 |
| Estimated completion | 30 October 2025 |
Drugs / interventions tested
- laughter therapy
- routine nursing care
Conditions studied
- Laughter Therapy — all drugs for Laughter Therapy →
- Psychological Well-being — all drugs for Psychological Well-being →
- Breast Cancer — all drugs for Breast Cancer →
- Distress — all drugs for Distress →
Sponsor
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Who can join
Adults 18 to 100, any sex, with Laughter Therapy or Psychological Well-being. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to examine the effect of laughter therapy applied to breast cancer patients before surgical intervention on distress, depression and psychological well-being of patients. This research will be carried out as an experimental research with a randomised control group. The population of the study will consist of breast cancer patients diagnosed with breast cancer in a city hospital and scheduled for surgery in the breast-endocrine surgery clinic. The research will be carried out with patients who meet the inclusion criteria and agree to participate in the study. The sample size for the study was calculated using the G\* Power 3.1.9.7 programme (Faul et al., 2007). In the calculation, since there was no similar study for two-way mixed design analysis of variance, the required sample size was calculated as 48, 24 in each group, based on the medium effect size (effect size f=0.25), 5% margin of error (alpha=0.05), inter-measurement correlation value 0.5 and 80% power (1-β=0.80). Considering the data losses, the number was increased by 20% and a total of 56 patients in the intervention and control groups constituted the sample of the study. Hypothesis(es): H1: The effect of laughter therapy applied to breast cancer patients on distress over time is different in the experimental and control groups. H2: The effect of laughter therapy applied to breast cancer patients on depression over time is different in the experimental and control groups. H3: The effect of laughter therapy applied to breast cancer patients on psychological well-being according to time is different in experimental and control groups. In obtaining the research data; Personal Information Form, Distress Thermometer, Psychological well-being scale prepared by the researchers in line with the literature will be used. The research data will be collected face-to-face through data collection forms from breast cancer patients diagnosed with breast cancer and scheduled for surgery in the breast-endocrine surgery clinic. Individuals who agree to participate in the study and meet the inclusion criteria will be assigned to the experimental and control groups by providing randomisation. Which caregivers will be in the intervention group and which will be in the control group will be determined according to the randomisation table determined by https://www.randomizer.org/ over the internet. Group 1: Intervention Group, Group 2: Control Group. Data collection tools will be applied to the individuals in the experimental and control groups as a pre-test. Individuals in the experimental group will receive laughter therapy three days a week for 30-45 minutes (6 sessions). Individuals in the control group will receive only standard nursing care. Data collection tools will be applied to the individuals in both groups for post-test, 1 and 3-month follow-up tests immediately after all laughter sessions with the experimental group are completed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07020962
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of laughter therapy
Trials testing the same drug.
- NCT06283810 — The Effects of Interpersonal Relationship Psychotherapy and Laughter Therapy · NA · completed
- NCT05806541 — The Effect Of Laughter Therapy On Self-Efficacy · NA · completed
- NCT05807698 — The Effect of Laughter Yoga on Psychological Well-Being · NA · unknown
- NCT05807685 — The Effect Of Laughter Therapy On Burnout And Guılt In Women · NA · unknown
- NCT05804812 — The Effect of Laughter Therapy in Women · NA · completed
Other recruiting trials for Laughter Therapy
Currently open trials in the same condition.
- NCT06116812 — The Effects of Laughter Yoga and Mindfulness-Based Stress Reduction (MBSR) Practices Applied to Women With Breast Cancer · NA · recruiting
Other Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization trials
Trials by the same sponsor.
- NCT07500285 — Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Ph · Phase 2 · not yet recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07390279 — Efficacy of Transcutaneous Pulsed Radiofrequency in Postherpetic Neuralgia · recruiting
- NCT07357922 — Serum Progesterone and Threatened Abortion During Lactation · not yet recruiting
- NCT07283250 — Development and Validation of the Air Quality Awareness Scale (AQAS) for Parents · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07020962 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
- Last refreshed: 13 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07020962.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing